2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Breast Neoplasms
29
Triple Negative Breast Neoplasms
13
Prostatic Neoplasms
13
Ovarian Neoplasms
12
Neoplasms
12
Neoplasm Metastasis
9
Fallopian Tube Neoplasms
6
Leukemia, Myeloid, Acute
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Carcinoma, Renal Cell
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Recurrence
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lung Neoplasms
2
Carcinoma, Ovarian Epithelial
2
mCRPC
1
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thrombocythemia, Essential
1
Solid Tumor
1
Sarcoma
1
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
talazoparib
×
Clear all
NCT04462809
2020-07-09
TALAMESO
Hospices Civils de Lyon
Phase 2
Unknown
40 enrolled